| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by (used in) financing activities | 22,702 | 23,024 |
| Net decrease in cash and cash equivalents | -10,196 | -10,966 |
| Cash and cash equivalents at beginning of period | 31,614 | - |
| Cash and cash equivalents at end of period | 21,418 | - |
Tvardi Therapeutics, Inc. (TVRD)
Tvardi Therapeutics, Inc. (TVRD)